DE69716104D1 - Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände - Google Patents
Chelate und metalchelate zur behandlung von durch freie radikale verursachte zuständeInfo
- Publication number
- DE69716104D1 DE69716104D1 DE69716104T DE69716104T DE69716104D1 DE 69716104 D1 DE69716104 D1 DE 69716104D1 DE 69716104 T DE69716104 T DE 69716104T DE 69716104 T DE69716104 T DE 69716104T DE 69716104 D1 DE69716104 D1 DE 69716104D1
- Authority
- DE
- Germany
- Prior art keywords
- chelates
- free radical
- radical conditions
- metal
- treating free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9613182.6A GB9613182D0 (en) | 1996-06-24 | 1996-06-24 | Method |
PCT/GB1997/001722 WO1997049409A1 (en) | 1996-06-24 | 1997-06-24 | Chelating agents and their metal chelates for treating free radicals induced conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69716104D1 true DE69716104D1 (de) | 2002-11-07 |
DE69716104T2 DE69716104T2 (de) | 2003-05-28 |
Family
ID=10795775
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69716104T Expired - Lifetime DE69716104T2 (de) | 1996-06-24 | 1997-06-24 | Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände |
DE69717447T Expired - Lifetime DE69717447T2 (de) | 1996-06-24 | 1997-06-24 | Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69717447T Expired - Lifetime DE69717447T2 (de) | 1996-06-24 | 1997-06-24 | Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen |
Country Status (14)
Country | Link |
---|---|
US (2) | US6258828B1 (de) |
EP (2) | EP0910360B1 (de) |
JP (2) | JP4359651B2 (de) |
CN (2) | CN1228694A (de) |
AT (2) | ATE225178T1 (de) |
AU (2) | AU720570B2 (de) |
BR (1) | BR9709942A (de) |
CA (2) | CA2258299A1 (de) |
DE (2) | DE69716104T2 (de) |
GB (1) | GB9613182D0 (de) |
IL (1) | IL127733A0 (de) |
NO (2) | NO985916L (de) |
NZ (2) | NZ333315A (de) |
WO (2) | WO1997049390A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
AU1770299A (en) * | 1997-12-23 | 1999-07-19 | Nycomed Imaging As | Nitric oxide releasing chelating agents and their therapeutic use |
AU770999C (en) | 1999-10-01 | 2005-04-21 | Ampio Pharmaceuticals, Inc. | Metal-binding compounds and uses therefor |
FR2823977B1 (fr) * | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
GB0117645D0 (en) | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
PT1744764E (pt) | 2004-04-22 | 2012-08-30 | Celator Pharmaceuticals Inc | Formulações lipossómicas de agentes antraciclina e análogos de citidina |
PT3311805T (pt) | 2005-08-31 | 2020-04-21 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
US8377969B2 (en) | 2007-12-14 | 2013-02-19 | Pledpharma Ab | Compounds for use in the treatment of cancer |
BR112012000262A2 (pt) * | 2009-07-06 | 2016-02-16 | Pledpharma Ab | composição farmacêutica, e, método de tratamento de uma condição. |
PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
US9187509B2 (en) | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
CA2917407C (en) | 2012-10-01 | 2023-03-14 | Mayo Foundation For Medical Education And Research | Complexes containing albumin-containing nanoparticles and antibodies to treat cancer |
MX2015005519A (es) | 2012-11-02 | 2015-07-17 | Pledpharma Ab | Metodos de tratamiento de cancer. |
US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
EP3399861A4 (de) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | Verfahren zur behandlung von krebs mit interferon |
EP3413874A4 (de) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | Behandlungen für blutkrebs |
AU2017238118A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
US11305020B2 (en) | 2016-03-21 | 2022-04-19 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
RU2019109209A (ru) | 2016-09-01 | 2020-10-05 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака |
KR20220151022A (ko) | 2016-09-01 | 2022-11-11 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체-pd-l1 결합제 조성물 |
US11311631B2 (en) | 2016-09-06 | 2022-04-26 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
KR20230011473A (ko) | 2016-09-06 | 2023-01-20 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Pd-l1 발현 암의 치료 방법 |
US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
US5223243A (en) * | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
US4842845A (en) * | 1987-05-08 | 1989-06-27 | Salutar, Inc. | Radioactive metal chelates for dipyridoxyl phosphate |
US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
-
1997
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en active IP Right Grant
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
- 1997-06-24 EP EP97928368A patent/EP0910360B1/de not_active Expired - Lifetime
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 EP EP97928369A patent/EP0936915B1/de not_active Expired - Lifetime
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en active IP Right Grant
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
-
1998
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0936915B1 (de) | 2002-10-02 |
JP2000513351A (ja) | 2000-10-10 |
CA2258299A1 (en) | 1997-12-31 |
JP4162263B2 (ja) | 2008-10-08 |
NO985916L (no) | 1999-01-25 |
EP0910360B1 (de) | 2002-11-27 |
IL127733A0 (en) | 1999-10-28 |
JP2000514044A (ja) | 2000-10-24 |
GB9613182D0 (en) | 1996-08-28 |
EP0936915A1 (de) | 1999-08-25 |
ATE228361T1 (de) | 2002-12-15 |
EP0910360A1 (de) | 1999-04-28 |
JP4359651B2 (ja) | 2009-11-04 |
ATE225178T1 (de) | 2002-10-15 |
CA2259150A1 (en) | 1997-12-31 |
NZ333315A (en) | 2000-07-28 |
AU720621B2 (en) | 2000-06-08 |
DE69717447D1 (de) | 2003-01-09 |
AU3268897A (en) | 1998-01-14 |
WO1997049409A1 (en) | 1997-12-31 |
WO1997049390A1 (en) | 1997-12-31 |
NO985916D0 (no) | 1998-12-17 |
DE69717447T2 (de) | 2003-09-11 |
NZ333357A (en) | 2000-08-25 |
US6258828B1 (en) | 2001-07-10 |
DE69716104T2 (de) | 2003-05-28 |
CN1228694A (zh) | 1999-09-15 |
CN1228703A (zh) | 1999-09-15 |
NO985917D0 (no) | 1998-12-17 |
BR9709942A (pt) | 1999-08-10 |
NO985917L (no) | 1999-01-25 |
US6147094A (en) | 2000-11-14 |
AU720570B2 (en) | 2000-06-08 |
AU3268997A (en) | 1998-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69716104T2 (de) | Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände | |
DE69826528D1 (de) | Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung | |
DE69703294D1 (de) | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten | |
MX9705235A (es) | Inhibidores de calpaina y/o catepsina b de oxazolidina substituida. | |
TR200102499T2 (tr) | Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi | |
ATE332708T1 (de) | Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält | |
DE69942680D1 (de) | Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie | |
DE69828042D1 (de) | Verfahren und zusammensetzung zur behandlung von krebs | |
DE69708100T2 (de) | Konjugate von cis-docosahexaensäure und paclitaxel | |
IL162214A0 (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
UA35589C2 (uk) | ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ | |
ATE367158T1 (de) | Quinazolinenon-enthaltende pharmazeutische zusammensetzungen zur verhütung von gefässneubildung und zur behandlung von bösartigen neubildungen | |
PT1109571E (pt) | Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos | |
WO2005011572A3 (en) | Combination of drugs for the treatment of neoplasms | |
WO1998036730A3 (de) | Zubereitungen für die behandlung von rosacea | |
ATE485818T1 (de) | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren | |
DE69633178D1 (de) | Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon | |
DE69938036D1 (de) | Mittel und verfahren zum schutz, zur behandlung und zur reparatur von bindegewebe | |
DE69423533D1 (de) | Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten | |
DK0885005T3 (da) | Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd | |
ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
DE69921096D1 (de) | Auf bibapcitide gegründete pharmaceutische zusammensetzungen für bildgebung und behandlung von thromben | |
ZA982808B (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: GE HEALTHCARE AS, OSLO, NO |
|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS LLP, LONDON, GB |
|
R082 | Change of representative |
Ref document number: 936915 Country of ref document: EP Representative=s name: J D REYNOLDS & CO., GB |